# Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

Study · id `cardio:ct-nct01001962` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01001962](<https://clinicaltrials.gov/study/NCT01001962>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01001962

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1054 participants.

## Technical summary

Registry record NCT01001962. Randomized; triple masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1054 participants (planned count; ClinicalTrials.gov record NCT01001962, source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT01001962, source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)
- Primary completion: 2019-01 (anticipated) (ClinicalTrials.gov record NCT01001962, source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)
- Completion: 2020-01 (anticipated) (ClinicalTrials.gov record NCT01001962, source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)
- Countries: Greece (ClinicalTrials.gov record NCT01001962, source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01001962-2015-04-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
- Acronym: PREHYPD
- Condition: Hypertension
- Condition: Type II Diabetes
- Intervention (Drug): empagliflozin
- Intervention (Drug): Metformin
- Lead sponsor: Aristotle University Of Thessaloniki
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Aristotle University Of Thessaloniki (`cardio:org-aristotle-university-of-thessaloniki`)

## Provenance

Content hash: 7de8025840aeabaf0206c88cdf9715969c0885ee256a04e2b4d53ef2fd80d7ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
